DNA molecules encoding human tissue plasminogen activator variants with decreased clearance, vectors, and host cells
US5246850A · kind A · utility
17Cited by
0References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 9, 1992 |
| Grant date | Sep 21, 1993 |
| Priority date | — |
| Expiry date | Jul 9, 2012 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Biologically active tissue plasminogen activator (t-PA) variants with decreased clearance as compared to wild-type t-PA are prepared, including variants that have one or more amino acid alterations in at least the kringle-1 and/or kringle-2 domain(s) of the molecule. DNA sequences can be prepared that encode the variants, as well as expression vectors incorporating the DNA sequences and host cells transformed with the expression vectors. The variants may be used in pharmaceutical preparations to treat a vascular disease or condition, or to prevent fibrin deposition or adhesion formation or reformation in mammals.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.